Provenge Improves Survival in mCRPC Patients Over Xtandi, Zytiga, Real-world Study Finds
News
Provenge (sipuleucel-T), by Dendreon Pharmaceuticals, is superior to Zytiga (abiraterone acetate) or Xtandi (enzalutamide) at prolonging the lives of men with metastatic castration-resistant prostate cancer (mCRPC) when added at any ... Read more